We investigated whether 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) could prevent acute increases in body fat and changes in omental and subcutaneous adipose tissue following the sudden transition from physical activity to physical inactivity. r What is the main finding and its importance? AICAR prevented fat gains following the transition from physical activity to inactivity to levels comparable to rats that remained physically active. AICAR and continuous physical activity produced depot-specific changes in cyclin A1 mRNA and protein that were associated with the prevention of fat gain. These findings suggest that targeting AMP-activated protein kinase signalling could oppose rapid adipose mass growth.
Introduction
Childhood physical inactivity is a major environmental factor driving increases in childhood obesity, which is associated with future adverse health outcomes, such as type 2 diabetes and cardiovascular disease (Manco & Dallapiccola, 2012) . Although more than 70 and 95% of girls and boys 6-8 years old, respectively, met recommended physical activity guidelines, fewer than 15 and 43% of girls and boys 12-14 years old, respectively, met the same requirements (Nader et al. 2008; Dumith et al. 2011) . Likewise, the prevalence of obesity increased from ß12% in children 2-5 years of age to ß18% among adolescents 12-19 years of age (Ogden et al. 2012) . Together, these trends highlight a growing public health crisis in youth, as physical inactivity and obesity are associated with increased risk of premature mortality, numerous chronic diseases and diminished quality of life (Booth et al. 2012) .
Adipose tissue is highly plastic and responds rapidly to periods of nutritional overabundance (Rutkowski et al. 2009 ). Expansion of adipose tissue, especially with visceral depots, by adipocyte hypertrophy promotes a pro-inflammatory phenotype that is simultaneous to the development of metabolic dysfunction and type 2 diabetes and cardiovascular disease risk (Antos & Potter, 2007; Rutkowski et al. 2009 ). Importantly, energy depletion early in life may influence fat growth later in life. Dulloo (2008) reported that in most cases, large decreases in body weight followed by weight recovery during infancy or childhood are accompanied by increases in body fat, specifically visceral fat, at a disproportionately faster rate than growth of lean tissue.
Since its development by Rhodes et al. (2003) , the rodent wheel lock (WL) model has been an invaluable tool to study how the transition from physical activity to physical inactivity affects different organ systems. In juvenile rats, researchers in our laboratory have shown drastic increases in visceral adiposity in rats following 1 week of WL, in comparison to both rats with continued free wheel access and rats never exposed to running wheels, highlighting the influences of ending reduced caloric expenditure on adipose tissue expansion and metabolism in maturing rats (Kump & Booth, 2005a; Company et al. 2013; Ruegsegger et al. 2015) .
One enzyme central to changes in energy state is AMP-activated protein kinase (AMPK). In addition to being a 'master regulator' of metabolism (Hardie, 2007) , AMPK inhibits early clonal expansion of pre-adipocytes, a process essential for adipogenesis, and prevents the expression of late adipogenic markers and enzymes essential for lipid synthesis and storage in mature adipocytes (Habinowski & Witters, 2001; Zhou et al. 2009 ). Pharmacological activation of AMPK with 5-aminoimidazole-4-carboxamide-1β-D-ribofuranoside (AICAR) reduces fat mass in rodents (Winder et al. 2000; Narkar et al. 2008) , and AMPK activation during exercise decreases triglyceride synthesis in white adipose tissue (Park et al. 2002; Kump & Booth, 2005b) . However, the effect of AICAR on mediating the detrimental effect of physical inactivity on adipose tissue growth and function is less well studied.
Therefore, the aim of this study was to determine whether AICAR could prevent increases in body fat following 7 days of WL in juvenile rats, as previously observed in our model (Company et al. 2013; Ruegsegger et al. 2015) , to levels comparable to those of rats with continuous wheel access. Additionally, we assessed mRNA expression in omental (OMAT) and subcutaneous adipose tissue (SAT) associated with hypoxia (Vegf, Hif1α), cell proliferation and differentiation (Cdk2, cyclin A1, cyclin D1) and metabolism (adiponectin, leptin), as well as energy homeostasis-regulating mRNAs in the hypothalamus (Pomc, Cart, Agrp, Npy, Lepr) . We hypothesized that increases in fat growth accompanying WL, in comparison to continuously running rats, would be attenuated by AICAR, and that this attenuation would be associated with reductions in adipogenic mRNA expression in OMAT and SAT and reduced orexigenic mRNA expression in the hypothalamus.
Methods

Experimental animals and design
All animal protocols were approved by the Institutional Animal Care and Use Committee at the University of Missouri (approval no. 8647) and complied with the US National Institutes of Health's Guide for the Care and Use of Laboratory Animals. The investigators understand the ethical principles under which Experimental Physiology operates, and the work presented complies with their animal ethics checklist. Male Wistar rats (n = 29; Charles River, Raleigh, NC, USA) were maintained in a 12 h-12 h light-dark cycle at 21-22°C, and food (Formulab Diet 5008; Purina, St Louis, MO, USA) and water were provided ad libitum. At 28 days of age, rats (n = 21) were introduced to voluntary running wheels (circumference, 1.062 m), with an additional group pair-housed without assess to voluntary running wheels (SED, n = 8). Running G. N. Ruegsegger and others 
distance was recorded using Sigma Sport BC 800 bicycle computers (Cherry Creek Cyclery, Foster Falls, VA, USA). At 49 days, rats with voluntary running wheels either maintained access to unlocked running wheels (RUN, n = 6) for the next 7 days or a stainless-steel rod was placed through the running wheel, thus prohibiting the running wheel from turning during the same time period. The wheel-lock model in our laboratory has been described previously (Kump & Booth, 2005a) . After wheel-lock, separate cohorts of rats received either vehicle (sterile 0.9% saline; WL, n = 7) or AICAR (500 mg kg −1 ; WL + AICAR, n = 8), via S.C. injection once daily for 7 days at 07.00 h. Additionally, SED and RUN rats also received S.C. sterile 0.9% saline injection during the same time frame. All rats were killed by CO 2 asphyxiation at 12.00-14.00 h, approximately 5-7 h after the final AICAR or vehicle injections, when 56 days old. Body weight and food intake were recorded weekly. Body composition was assessed at the time of WL and on the day of killing.
Assessment of body composition and tissue collection
Body composition was assessed twice using a dual-energy X-ray absorptiometry (DXA) machine calibrated for rats (QDR 4500A; Hologic, Bedford, MA, USA). Seven days before the end of the experiment, rats were anaesthetized by inhalation of isoflurane before the DXA scan. All scans were repeated on the day of killing, immediately after CO 2 asphyxiation, which was immediately followed by tissue removal. The gastrocnemius, soleus, triceps and OMAT were removed and weighed. Subcutaneous adipose tissue from the dorsolumbar region was also removed but not weighed. Tissue from the arcuate nucleus of the hypothalamus (Arc) was extracted using a 2-mm-thick punch tool and brain sectioning apparatus (Braintree Scientific, Braintree, MA, USA). Tissue plugs from 2-mm-thick coronal brain slices were identified using a rat brain atlas (Paxinos & Watson, 1998) . We chose to analyse transcripts from the Arc because of their important roles in regulating appetite and energy balance (Morton & Schwartz, 2001; Williams & Schwartz, 2005) . Tissues were stored at −80°C until processing.
RNA isolation, cDNA synthesis and qRT-PCR
RNA isolation, cDNA synthesis and qRT-PCR of OMAT, SAT and Arc samples were performed as previously described (Ruegsegger et al. 2015) . Gene-specific primers were constructed using PrimerExpress3.0 software (Applied Biosystems, Foster City, CA, USA; Table 1 ). Messenger RNA expression values were quantified using the 2 − C t method, whereby C t = 18S C t -target gene C t . One SAT mRNA sample was removed because of poor RNA quality.
Western blotting
Western blotting was performed on OMAT and SAT samples as previously described (Ruegsegger et al. 2015) . Equal loading was verified by Ponceau S (Sigma). Primary antibodies for phospho-AMPKα1/2 (Thr 172; 1:500, #sc-33524; Santa Cruz Biotechnology; Dallas, TX, USA), AMPKα1/2 (1:500, #sc-74461; Santa Cruz Biotechnology; Dallas, TX, USA), phospho-ACC (Ser 78/Ser 80; 1:500, #sc-30447-R; Santa Cruz Biotechnology; Dallas, TX, USA), phospho-HSL (Ser 565; 1:1000, #4137; Cell Signaling; Danvers, MA, USA) and cyclin A1 (1:500, #CCNA1; Signalway Antibody; College Park, MD, USA) were diluted in Tris-buffered saline with Tween 20 (TBST) with 5% bovine serum albumin and applied to membranes overnight at 4°C. Next, HRP-conjugated secondary antibody (1:1,000; Cell Signaling) was applied to membranes for 1 h at room temperature in TBST with 5% non-fat milk. Before exposure, ECL substrate (Pierce Biotechnology; Waltham, MA, USA) was applied for 5 min. Band densitometry was obtained using a Kodak Prevention of fat gain accompanying inactivity 4000R Imager and Molecular Imagery Software (Kodak Molecular Imaging Systems; Rochester NY, USA).
Statistical analysis
Data were analysed using SigmaPlot 12.0 (Systat Software; San Jose, CA, USA) with an α value of 0.05. Values are reported as means ± SD. Outcome measures for between-group comparison were assessed with one-way ANOVA. Changes in body weight, food intake and running distance over the duration of the study were assessed by two-way (age × treatment) ANOVA. Holm-Sidak post hoc analysis were performed when appropriate. Pearson correlations were used to assess relationships between OMAT and SAT mRNA expression, changes in fat mass and body fat percentage, and OMAT and SAT p-AMPK levels. No significant correlations were present when data were analysed by individual groups. Therefore, all Pearson correlations were calculated encompassing all experimental animals.
Results
Animal characteristics
Body weight was increased in SED rats compared with the other experimental groups in the final 3 weeks of the study (F 3,150 = 14.46, P < 0.001; Fig. 1A ). No group differences were observed in food intake for the study duration (F 3,106 = 1.81, P = 0.15; Fig. 1B ) or in running distance up to the point of wheel lock (F 3,72 = 1.24, P = 0.30; Fig. 1C ). Animal characteristics at the time of sacrifice are presented in Table 2 . Notably, both RUN and WL + AICAR treatments resulted in decreases in OMAT mass (F 3,25 = 8.66, P < 0.001) and OMAT mass normalized to body weight (F 3,25 = 9.30, P < 0.001) compared with both SED and WL groups. From the time of WL until study termination, increases in body fat percentage (F 3,25 = 7.07, P < 0.001; Fig. 2A ) and fat mass (F 3,25 = 7.65, P < 0.001; Fig. 2B ) were attenuated in both RUN and WL + AICAR compared with both SED and WL groups. However, the differences in fat percentage and mass were independent of the differences lean mass (F 3,25 = 0.53, P = 0.66) or food intake (F 3,25 = 0.96, P = 0.43; data not shown).
Omental and subcutaneous adipose tissue mRNA and protein expression
Omental and subcutaneous adipose tissue mRNA expression data are shown in Fig. 3 . Surprisingly, no differences in SAT mRNA expression were observed (Fig. 3C ). In OMAT, Hif1α mRNA expression was decreased in WL (F 3,25 = 5.04, P = 0.007), and adiponectin mRNA expression was decreased in WL + AICAR (F 3,25 = 8.03, P < 0.001; Fig. 3A) . Additionally, in OMAT, leptin mRNA expression was decreased in WL and RUN compared with SED, and further decreased in WL + AICAR (F 3,25 = 8.02, P < 0.001). Intriguingly, cyclin A1 mRNA expression in OMAT was decreased in RUN and WL + AICAR compared with SED and WL (F 3,25 = 3.87, P = 0.021) and was positively correlated with changes in fat mass from the time of WL to the end of the Values are means ± SD (n = 6-8 per group). * P < 0.05 SED versus WL; # P < 0.05 SED versus WL + AICAR; & P < 0.05 SED versus RUN. Note that data include one rat that ran an exceptionally long distance in the RUN group, contributing to the large SD. study for all groups (r = 0.37, P = 0.03; Fig. 3B ). Similar observations concerning cyclin A1 mRNA expression in SAT were not observed (Fig. 3D) . Also in OMAT, Hif1α mRNA expression was negatively correlated with changes in fat mass (r = −0.39, P = 0.04) and cyclin A1 mRNA expression (r = −0.58, P = 0.001; data not shown). Similar to its mRNA expression, cyclin A1 protein in OMAT was increased in WL (F 3,25 = 8.004, P < 0.001; Fig. 3E ), whereas no differences in cyclin A1 protein were detected in SAT (F 3,25 = 0.23, P = 0.87; Fig. 3G ). Additionally, cyclin A1 protein in OMAT was positively correlated with increases in fat mass from the time of WL until study termination (r = 0.62, P < 0.001; Fig. 3F ).
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Similar observations were not made in SAT (r = 0.18, P = 0.33; Fig. 3H ).
Downstream markers of AMPK activity and correlations with mRNA expression
Surprisingly, one-way ANOVA did not detect betweengroup differences in the p-AMPK/AMPK ratio (F 3,25 = 1.87, P = 0.16), p-HSL (F 3,25 = 0.18, P = 0.91) or p-ACC (F 3,25 = 0.37, P = 0.77) protein levels in OMAT (Fig. 4A) . Likewise, no differences in protein levels in SAT were observed for the p-AMPK/AMPK ratio ( ) . B, cyclin A1 mRNA expression in OMAT showed a significant positive correlation with changes in fat mass during the 7 day period from the time of wheel lock until the termination of the exeperiment. D, in SAT, cyclin A1 mRNA expression was not correlated with changes in fat mass. E and F, likewise, cyclin A1 protein was increased in WL in OMAT (E) and showed a significant positive correlation with changes in fat mass from the time of wheel lock until study termination (F). No differences in cyclin A1 protein were G. N. Ruegsegger and others detected in SAT (G), and cyclin A1 protein in SAT was not correlated with changes in fat mass from the time of wheel lock until study termination (H). I, representative cyclin A1 Western blot bands for OMAT and SAT. Values are shown as means + SD (n = 6-8 per group). Different letters designate statistically significant differences (P < 0.05).
(F 3,25 = 1.06, P = 0.38; Fig. 4B ). We speculate that these negative findings could be attributed to the 5-7 h delay between the final period of voluntary wheel running or AICAR injection and tissue collection. It was shown that p-AMPK Thr 172 concentration significantly peaked at 30 min postexercise in the vastus lateralis muscle of 23-year-old men after they performed three sets of eight repetitions of maximal eccentric knee contractions, but p-AMPK Thr 172 was not significantly increased at 15 or 60 min postexercise in these subjects (Gehlert et al. 2012) .
Despite the lack of group differences in the above measures of AMPK activity, we next assessed relationships between p-AMPK, p-HSL and p-ACC protein with mRNA expression in OMAT or SAT given findings that AMPK is an upstream regulator of cell cycle-related (Zhuang & Miskimins, 2008) and Hif1α (Lee et al. 2003) gene expression. In OMAT, p-AMPK protein was negatively correlated with OMAT cyclin A1 mRNA expression (r = −0.42, P = 0.02; Fig. 4C ), positively correlated with OMAT Hif1α mRNA expression (r = 0.49, P < 0.01; Fig. 4D ) and showed a trend to a negative correlation with body fat percentage at the end of the experiment (r = −0.34, P = 0.07; Fig. 4E ). In contrast to OMAT, p-AMPK levels in SAT were not correlated with SAT cyclin A1 mRNA expression (r = −0.03, P = 0.86; Fig. 4F ), SAT Hif1α mRNA expression (r = −0.14, P = 0.47; Fig. 4G ) or body fat percentage at the end of the experiment (r = 0.13, P = 0.52; Fig. 4H ). No significant relationships were observed between p-HSL or p-ACC protein and mRNA expression in OMAT or SAT.
Hypothalamic mRNA expression
One-way ANOVA found no differences in Arc Pomc, Cart, Agrp, Npy or Lepr mRNA expression among the four groups, as shown in Fig. 5 .
Discussion
Here, were report new findings that AICAR treatment prevents gains in fat mass accompanying the 1 week transition from physical activity to physical inactivity. Additionally, the effect of AICAR on fat gain following WL was similar to the effect of continuous running on fat gain during the same period. The prevention of fat gain in WL + AICAR and RUN groups, in comparison to WL conditions, was associated with reductions in OMAT, but not SAT, cyclin A1 mRNA expression and protein content, permitting the hypothesis for reductions in cell division and proliferation in OMAT, but not SAT.
Furthermore, p-AMPK levels in OMAT were negatively correlated with OMAT cyclin A1 mRNA expression and trended to correlate with decreased body fat percentage at the end of the experiment, whereas similar responses were not observed in SAT. Additionally, the prevention of fat gain in RUN and WL + AICAR occurred independent of both changes in food intake during the final week of the study and expressions of five Arc mRNAs, suggesting that changes in energy intake were not the primary determinant of changes in body fat in this experiment. Although associative, these findings collectively suggest a hypothesis that cyclin A1 mRNA and protein expression could partly mediate the separate effects of AICAR supplementation and continuous physical activity on the continued hindrance of OMAT mass expansion.
Our observation that AICAR treatment in conjunction with WL prevented gains in omental and total body fat masses is similar to previous studies demonstrating that AICAR reduced intra-abdominal fat mass (Winder et al. 2000; Buhl et al. 2002; Narkar et al. 2008) . Furthermore, the short duration of our study (1 week) compared with previous reports (4-8 weeks) suggests that even short treatments with AICAR may produce drastic changes in adipose tissue phenotype in physically active rats undergoing detraining. Gaidhu et al. (2011) reported that AICAR-treated rats that never had running, or any type of added physical activity, during their experiment had increased dark-cycle energy expenditure by 8 and 16% after 4 and 8 weeks, respectively. However, prevention of fat increase with AICAR treatment differed, as Gaidhu et al. (2011) examined fat gain in growing male rats, whereas we tested fat regain. In the final week of our present study, fat masses remained similar in the rat group that ran voluntarily when compared with the group receiving AICAR treatment undergoing the detraining week after weeks of running. A limitation of the present study was the use of group housing in SED rats and single housing in the other three groups, which could have influenced changes in fat gain, as previously data demonstrate less variability in fat gain in single versus group-housed mice (Nagy et al. 2002) . However, given the considerable difference in fat gain between the WL and WL + AICAR groups, which were both single housed, we speculate that AICAR was the predominant effector of the inhibition of fat growth, rather than the single versus group housing effect, because the WL-only group tended to gain a greater percentage of body fat than the SED group.
To explore potential differences in adipose tissue phenotype further, we analysed selective mRNA expression in OMAT and SAT. Intriguingly, our mRNA Prevention of fat gain accompanying inactivity (SAT; B) . However, p-AMPK protein expression in OMAT showed a significant negative correlation with cyclin A1 (C) and significant positive correlation with Hif1α (D) mRNA expression in OMAT, and tended to shows negative association with body fat percentage at the end of the experiment (E). p-AMPK protein expression in SAT was not correlated with cyclin A1 (F) or Hif1α (G) mRNA expression in SAT, or with body fat percentage at the end of the experiment (H). I, representative p-AMPK, AMPK, p-HSL and p-ACC Western blot bands for OMAT and SAT. Values are shown as means + SD (n = 6-8 per group). Different letters designate statistically significant differences (P < 0.05). Note that in C-H, outlier data points are denoted with an asterisk ( * ). Pearson correlations were performed with and without ( * by r value) these data points.
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findings hint that RUN and AICAR treatment might reduce cell proliferation of OMAT compared with WL, as detailed next. Cyclin A1 protein functions to promote cell proliferation and survival by controlling crucial points of the cell cycle, and its mRNA is indicative of cell proliferation (Girard et al. 1991; Pagano et al. 1992) . Here, cyclin A1 mRNA and protein in OMAT were decreased in RUN and WL + AICAR compared with WL and negatively correlated with decreases in fat mass from the time of WL, suggesting that continuous exercise and AICAR may inhibit physical inactivity-induced proliferation and/or differentiation of pre-adipocytes in a similar manner. Both AICAR (Habinowski & Witters, 2001; Dagon et al. 2006; Lee et al. 2011 ) and exercise training (Sakurai et al. 2010) have been shown to inhibit pre-adipocyte differentiation and adipogenesis. However, the results of the present study are limited in that we did not assess adipocyte hypertrophy or hyperplasia. Given previous observations following WL in 56-day-old rats (Company et al. 2013) , we speculate that RUN and WL + AICAR could have prevented fat growth compared with WL via the prevention of adipocyte hyperplasia. Surprisingly, no differences in cyclin D1 or Cdk2 mRNA, two additional mRNAs involved in cell cycle regulation and cell proliferation, were observed between groups in OMAT. Another supportive observation is that the downregulation of Hif1α mRNA by WL in OMAT in our study is consistent with previous reports demonstrating that knockdown of Hif1α protein enhances adipogenesis (Wagegg et al. 2012) .
AMPK is hypothesized to be a physiological regulator of adipogenesis (Dagon et al. 2006; Daval et al. 2006) . We observed a negative correlation between p-AMPK levels and cyclin A1 mRNA expression in OMAT, and a trend for decreased body fat to correlate with p-AMPK levels in OMAT. Findings from breast cancer cells and oesophageal squamous cell carcinomas suggest that AMPK is an upstream regulator of cyclin protein expression and cell cycle arrest (Zhuang & Miskimins, 2008; Cai et al. 2015) , although, to our knowledge, similar measurements have not been made in adipocytes. However, several reports demonstrate that AICAR treatment inhibits adipocyte differentiation in vitro (Habinowski & Witters, 2001; Dagon et al. 2006) . Therefore, we hypothesize that interactions between AMPK and cyclin A1 could mediate differences in OMAT fat gain in SED and WL compared with RUN and WL + AICAR, because causal relationships were not determined in the present study. Additionally, our observation that p-AMPK levels were positively correlated with Hif1α mRNA in OMAT is in line with previous findings implicating AMPK as a crucial controller of Hif1α regulation (Lee et al. 2003) . Taken together, we speculate that physical activity and AICAR, potentially through similar molecular mechanisms associated with reduced cell proliferation, could act as brakes on adipose tissue expansion in our experimental model. Once these brakes are removed (i.e. physical inactivity/termination of drug treatment), adipose tissue could expand at an accelerated rate (i.e. 'catch-up' fat). Future studies are needed to determine causal relationships between AMPK, cell proliferation and differentiation and adipose tissue growth following WL, as well as to compare the molecular mechanisms by which pharmacological treatments and physical activity influence adipose tissue growth to determine whether they act though the same downstream pathway.
Surprisingly, we did not observe changes in mRNA expression in SAT following either continuous wheel running or 1 week of AICAR treatment. Previous findings show that chronic AICAR treatment reduces adiposity while increasing mitochondrial content in both visceral and subcutaneous adipose tissue (Gaidhu et al. 2011) . However, our observation suggests that factors producing changes in energy homeostasis (i.e. voluntary physical activity or pharmacological treatment) might initially have greater effects on OMAT rather than on SAT, at least with concern for the mRNAs presented herein. This notion is in line with several reports demonstrating that exercise training (Despres et al. 1991; Mourier et al. 1997; Ross et al. 2004; Chaston & Dixon, 2008) and the anti-obesity drugs orlistat and sibutramine (Kamel et al. 2000; Kelley et al. 2004 ) preferentially reduce visceral adipose tissue compared with SAT. Future research is needed to clarify depot-specific effects of physical inactivity or activity and AICAR treatment on adipose tissue growth and function.
In the present study, differences in adipose tissue gain between WL, RUN and WL + AICAR occurred independent of changes in food intake. Rapid increases in body fat, despite decreases in food intake to control levels, in WL have been observed previously (Company et al. 2013; Ruegsegger et al. 2015) , highlighting the importance of energy expenditure on adipocyte expansion during endurance types of exercise. Consistent with lack of change in food intake, we did not find differences in appetite Prevention of fat gain accompanying inactivity control mRNAs in the Arc. These findings are in contrast to previous findings demonstrating that chronic AICAR treatment (Gaidhu et al. 2011) and voluntary physical activity (Krawczewski Carhuatanta et al. 2011) enhance leptin signalling in the Arc. We speculate that the levels of voluntary running and time course of AICAR injection performed in the present study might have been below a threshold needed to stimulate adaptations in Arc mRNA expression. Additionally, because cage activity was not assessed in the present study, the possible influence of changes in cage activity following AICAR treatment on fat gain cannot be ignored, as chronic AICAR treatment has been shown to increase ambulatory activity (Gaidhu et al. 2011) .
In conclusion, our data suggest that 1 week of WL produces rapid increases in fat gain that are prevented by AICAR supplementation. Moreover, the inhibition of body fat increase accompanying AICAR mirrored attenuations in body fat accompanying continuous voluntary wheel running, and was associated with the downregulation of cyclin A1 mRNA and protein in OMAT in both RUN and WL + AICAR. Although catch-up enlargement of adipose tissue upon the cessation of physical activity may be a natural survival adaptation to accrue adipose tissue in times of 'feast and famine' (Neel, 1962) , this adaptation is maladaptive in modern society, where food intake is often ad libitum and potentially leads to rapid increases in adipose tissue-initiated low-grade inflammation (Ruegsegger et al. 2015) . AICAR also has an AMPK-independent inhibition of inflammation (Jhun et al. 2004; Kuo et al. 2008; Boss et al. 2016) , which could also abate gains in inflammatory adipose tissue when long periods of inactivity occur after physical activity. Although this study underscores the importance of continuous physical activity levels to sustain a healthy adipose tissue phenotype, these data also suggest that AICAR supplementation might prevent gains in adipose tissue during periods of physical inactivity. As the majority of weight loss is regained in obesity (Anderson et al. 2001; Weiss et al. 2007) , Maclean et al. (2011) have concluded that strategies to counter weight regain will need to be as comprehensive as the 'biological adaptations they are attempting to counter' . Future studies could pursue the intriguing evidence of the present study that targeting AMPK signalling could have beneficial effects in opposing rapid adipose mass growth in the face of forced reductions in physical activity during medically induced periods of physical inactivity. 
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